ACE-i i sartany a COVID-19 – najnowsza meta analiza 52 badań (n= 101 949)

Ranu Baral i wsp. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19A Systematic Review and Meta-analysis.
JAMA Netw Open. 2021;4(3):e213594

Meaning The study’s findings suggest that ACEIs and ARBs may be associated with protective benefits for patients with COVID-19 and that patients may continue receiving ACEIs and ARBs for the treatment of any condition without an increased risk of worse outcomes unless specifically advised to avoid them by treating clinicians.

JAMA Network Open, 31 marca 2021

0 replies on “ACE-i i sartany a COVID-19 – najnowsza meta analiza 52 badań (n= 101 949)”